Based on these data, the aim of the present open-label, randomized feasibility trial is to evaluate the feasibility, efficacy and tolerability of neoadjuvant everolimus plus letrozole versus neoadjuvant FEC chemotherapy in treating postmenopausal women with ER-positive, HER2-negative breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.